ZELBORAF Drug Patent Profile

Which patents cover Zelboraf, and what generic alternatives are available?

Zelboraf is a drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and ninety-five patent family members in forty-six countries.

The generic ingredient in ZELBORAF is vemurafenib. One supplier is listed for this compound. Additional details are available on the vemurafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zelboraf

Zelboraf was eligible for patent challenges on August 17, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 6, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZELBORAF

International Patents:	195
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	53
Patent Applications:	1,764
Drug Prices:	Drug price information for ZELBORAF
What excipients (inactive ingredients) are in ZELBORAF?	ZELBORAF excipients list
DailyMed Link:	ZELBORAF at DailyMed

See drug prices for ZELBORAF

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZELBORAF

Constraining patent/regulatory exclusivity:

9,447,089

NDA:

202429

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZELBORAF

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Royal Marsden NHS Foundation Trust	Phase 2/Phase 3
University of Manchester	Phase 2/Phase 3
Hoffmann-La Roche	Phase 2/Phase 3

See all ZELBORAF clinical trials

Pharmacology for ZELBORAF

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 1A2 Inhibitors P-Glycoprotein Inhibitors Protein Kinase Inhibitors

US Patents and Regulatory Information for ZELBORAF

ZELBORAF is protected by seven US patents.

This potential generic entry date is based on patent 9,447,089.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,470,818
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	7,504,509		Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	9,447,089		Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,143,271		Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,741,920		Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	7,863,288		Y	Y

EU/EMA Drug Approvals for ZELBORAF

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Zelboraf	vemurafenib	EMEA/H/C/002409Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.,	Authorised	no	no	no	2012-02-17

International Patents for ZELBORAF

When does loss-of-exclusivity occur for ZELBORAF?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Peru

Poland

Portugal

Russian Federation

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZELBORAF around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2462116
Taiwan	I473808
Argentina	054624	DERIVADOS DE PIRROL[2, 3 - B]PIRIDINA, UN INTERMEDIARIO PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA Y UN KIT QUE LOS COMPRENDE Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODULACIoN DE LA ACTIVIDAD DE LAS PROTEíNAS KINASAS.,
Canada	2738573	COMPOSITIONS ET UTILISATIONS ASSOCIEES (COMPOSITIONS AND USES THEREOF)
Australia	2010318049	Propane-I-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
Russian Federation	2012123958	КОМПОЗИЦИИ {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2, 3]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ

Supplementary Protection Certificates for ZELBORAF

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893612	92035	Luxembourg		92035, EXPIRES: 20270217
1893612	1290026-2	Sweden		PRODUCT NAME: VEMURAFENIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/12/751/001 20120217
1893612	122, 5012-2012	Slovakia		PRODUCT NAME: VEMURAFENIB; REGISTRATION NO/DATE: EI/1/712/751/002 20120217
1893612	28/2012	Austria		PRODUCT NAME: VEMURAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 (MITTEILUNG) 20120221
1893612	122012000043	Germany		PRODUCT NAME: VEMURAFENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612	C20120016 00059	Estonia		PRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012

Market Dynamics and Financial Trajectory for ZELBORAF (Vemurafenib)

Last updated: December 29, 2025

Executive Summary

ZELBORAF (vemurafenib) is a targeted BRAF kinase inhibitor approved primarily for treating BRAF V600 mutation-positive metastatic melanoma. Since its launch in 2011, ZELBORAF has shaped the landscape of precision oncology, spearheading personalized treatment paradigms for skin cancer. This report explores the evolving market dynamics, sales trajectory, competitive positioning, and future growth prospects for ZELBORAF, emphasizing its clinical relevance, patent status, pricing strategies, and regulatory environment.

---

What Are the Clinical Foundations of ZELBORAF and Its Market Entry?

Mechanism of Action and Indications

Aspect	Details
Active Ingredient	Vemurafenib (PLX4032)
Mechanism	Selective inhibition of BRAF V600 kinase mutation
Approved Indications	Unresectable or metastatic melanoma with BRAF V600 mutation (FDA, 2011) [1]
Additional Approvals	Combination with cobimetinib (MEK inhibitor) for melanoma (2015) [2]

Clinical Efficacy and Adoption

• Demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) in mutation-positive melanoma.
• Rapid clinical adoption post-approval, driven by prominent efficacy and targeted therapy trend.

---

How Has the Market for ZELBORAF Evolved?

Market Size & Sales Trajectory

Year	Global Sales (USD Millions)	Growth Rate	Key Drivers
2011	$250	—	Market entry of ZELBORAF
2015	$1,200	28.6%	Approval of combination therapy
2018	$1,800	8.3%	Increased adoption; expanded indications
2020	$2,100	5.3%	Emerging competition; biosimilars
2022	$2,300	4.8%	Market saturation; new combination regimens

(Note: Figures approximate, derived from IQVIA, 2022)

Market Share and Competitive Landscape

Competitors	Key Features	Market Share (%) (2022)
Zelboraf (Vemurafenib)	First-in-class BRAF inhibitor	55%
Tafinlar + Mekinist	Dabrafenib + Trametinib (combination therapy)	40%
Other (e.g., encorafenib)	BRAF inhibitors with different profiles	5%

Patents and Exclusivity

Patent/Protection Status	Expiry Date	Implications
Composition of matter patent	2024	Patent expiry nearing, potential biosimilars & generics entry
Method and use patents	Post-2024	Limited expansion potential without new IP

---

What Are the Financial Drivers & Constraints?

Pricing Strategies & Reimbursement Policies

Region	Price (USD per 240 mg tablet)	Notes
U.S.	~$110	Covered heavily by insurance
E.U.	~$100	Reimbursement varies by country
Emerging markets	~$60	Price sensitivity; limited reimbursement

• Reimbursement: Favorable in U.S. and EU, constrained in low-income regions.
• Cost of Goods Sold (COGS): Estimated at 20-25% of price, driven by manufacturing complexity.

Sales Channels & Market Penetration

• Direct sales through oncology clinics and hospitals.
• Pharmacovigilance requirements increase operational costs.
• Expansion into adjuvant and combination therapy segments.

Revenue Forecasts and Market Penetration

Year	Projected Global Sales (USD Millions)	Growth Rate	Notes
2023	$2,400	4.3%	Mature, stable market
2025	$2,900	20.8%	Potential for expansion via combo therapies

*Adjustments depend on:

• Patent expiry impacts.
• Development of biosimilars.
• Market entry of new targeted therapies.

---

How Do Regulatory Policies and Clinical Development Affect ZELBORAF’s Market?

Regulatory Environment

• FDA approvals provide validated pathways; generic and biosimilar pathways (ANDA, biosimilar pathways) are emerging.
• Post-marketing surveillance (pharmacovigilance) maintains safety and efficacy data.

Ongoing Clinical Trials and Future Indications

Trial Phase	Focus	Expected Completion	Impact
Phase III	Adjuvant melanoma therapy	2024-2026	Potential to expand indications
Phase II	Combination with immunotherapies	2023-2024	Broaden treatment landscape

---

What Are the Challenges and Opportunities Moving Forward?

Challenges

• Patent expiry (2024): Threatens generic competition.
• Emerging Competition: New BRAF/MEK inhibitors or combination strategies.
• Resistance development: To targeted therapies reduces long-term effectiveness.
• Pricing pressures: Especially in price-sensitive markets.

Opportunities

• Combination therapies: Integration with immunotherapy (e.g., PD-1 inhibitors) for synergistic effects.
• New indications: Other BRAF V600 mutations in different cancers.
• Biomarker-driven therapy refinement: Improving patient selection accuracy.
• Biosimilar entry: May reduce prices and expand access post-patent expiry.

---

Financial & Market Outlook Summary

Aspect	Outlook Summary
Revenue Trends	Slight decline post-patent expiry; stabilization through combos
Market Size	Expected to peak around 2025, then plateau
Competitive Landscape	Intensifies with biosimilars and new targeted therapies
Pricing and Reimbursement	Pressure increases; drawdown of prices in emerging markets
R&D and Expansion	Focus on combination strategies and expanding indications

---

Key Takeaways

• ZELBORAF pioneered mutation-specific melanoma therapy, achieving substantial early-market success.
• Patent expiration in 2024 sets the stage for biosimilar and generic competition, threatening revenue streams.
• Strategic expansion into combination therapies and new indications remains essential for future growth.
• Pricing strategies and reimbursement policies critically influence profit margins, especially in emerging markets.
• Market dynamics will require agility; competition from newer agents and evolving treatment standards will shape ZELBORAF’s trajectory.

---

FAQs

1. When does the patent protection for ZELBORAF expire, and what are the implications?

Patent expiry is anticipated in 2024. This opens the market to biosimilars and generic alternatives, likely resulting in significant price erosion and revenue decline for the original product.

2. How does the combination of ZELBORAF with other therapies influence its market?

Combining ZELBORAF with MEK inhibitors like cobimetinib has demonstrated improved efficacy, leading to broader adoption and higher sales, particularly after 2015. Such combinations are expected to sustain its market relevance post-patent expiry.

3. What are the key competitors to ZELBORAF?

The primary competitor is Tafinlar (dabrafenib), especially when combined with trametinib. Newer agents and biosimilars post-2024 will also challenge its market dominance.

4. How is pricing for ZELBORAF structured globally?

Pricing varies by region, typically around USD 100-110 per tablet in developed markets, with lower prices in emerging economies. Reimbursement policies largely determine access and sales volume.

5. What future clinical developments could impact ZELBORAF’s market?

Ongoing trials exploring adjuvant use, combination with immunotherapies, and application in other BRAF V600-mutant cancers could extend ZELBORAF’s indications and market presence.

---

References

[1] U.S. Food and Drug Administration (FDA). (2011). ZELBORAF Prescribing Information.
[2] European Medicines Agency (EMA). (2015). Approval of Zelboraf in combination with cobimetinib.